logo-loader
viewValiRx PLC

ValiRx updates on second round of funding discussions

The company has provided some detail on a potential second financing round

graphic with the word funding
A follow-on convertible and warrant funding arrangement is in negotiation

ValiRx Plc (LON:VAL) updated on a potential second round of funding as it provided some minor and revised guidance on the first financing round.

Last month the drug developer said it had brokered a subscription agreement with European High Growth Opportunities SF for £1.278mln at 0.6p done in three equal £426,000 tranches. ValiRx said today that the shares related to the second payment instalment will be admitted for trading on May 23 rather than May 21.

A follow-on convertible and warrant funding arrangement with the same investor is in negotiation, though definitive documentation has yet to be inked and shareholder approval needs to be sought and given, it added.

However, the company pointed out that the first £500,000 tranche of the planned second funding round has what is called a ‘make whole amount’ that ensures the subscription price can be reduced if ValiRx’s share price falls. For more information on how this calculated, click here.

There is also a £150,000 break fee plus and an additional amount in the event the share price falls.

“The company advises that it is commencing discussions with the Investor to amend the basis that is used to calculate the quantum of the break fee,” ValiRx said.

“The company does not expect the outcome of these discussions on the quantum of the Break Fee to have an adverse impact on the company.”

Quick facts: ValiRx PLC

Price: 0.1467 GBX

AIM:VAL
Market: AIM
Market Cap: £1.5 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ValiRx PLC named herein, including the promotion by the Company of ValiRx PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: Green light for ValiRx to increase dose of VAL201

Top stories from the Proactive Investors UK newsroom. ValirX (LON:VAL) has received a boost for its prostate cancer treatment VAL201 after UK regulators approved a substantial increase in the doses allowed in future clinical trials. The phase I/II trial so far has met all primary and...

on 20/6/19

RNS

Placing & Issue of Equity

50 minutes ago

Price Monitoring Extension

4 days, 21 hours ago

Half-year Report

2 weeks, 4 days ago

Company Update

2 weeks, 6 days ago

VAL201 Update

on 10/9/19

2 min read